Medicare drug negotiations poised to drop Part D premiums up to 15% long-term

Washington, D.C., continues to navigate discussions about giving Medicare the ability to negotiate drug prices, but analysts already foresee long-term savings for Part D premiums should it be approved.

Advertisement

The Kaiser Family Foundation projects that Part D beneficiaries are expected to see 9 percent savings come 2023, rising to 15 percent savings by 2029, according to an Aug. 12 report. Per capita savings are to the tune of $39 annually for a beneficiary in 2023 and $85 annually in 2029.

The report also anticipates a base annual beneficiary premium shift to $440 in 2023 and $560 in 2029.

Estimates are based on the most recent iteration of the Elijah E. Cummings Lower Drug Costs Now Act.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.